A dialysis client with CKD-mineral and bone disorder is scheduled for denosumab and reports new perioral tingling and muscle spasms. Which action is best?
1Administer denosumab now and schedule the next calcium test at the routine annual visit.
2Proceed because regular dialysis prevents clinically important treatment-related hypocalcemia.
3Hold denosumab and urgently assess calcium and the CKD-mineral bone plan with the authorized team.✓ Correct answer
4Ask the client to take an additional denosumab dose independently after dialysis.
Explanation
Advanced CKD and CKD-mineral bone disorder increase the risk of severe denosumab-associated hypocalcemia; symptoms require urgent evaluation before dosing.
Quick answer Treat symptoms as possible severe hypocalcemia in advanced CKD.
Why this is correct FDA added a boxed warning because denosumab can cause severe, sometimes life-threatening hypocalcemia in advanced CKD, especially with CKD-mineral bone disorder.
Easy analogy or mental picture Think of medication safety as a control panel: identify the dangerous signal, change the correct control, and verify the response.
Memory hook Cue, action, response, reassessment.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving the continuing indication.
Why the other choices are wrong Options that delay escalation, ignore a contraindication, or change therapy without authorization do not close the safety loop.
References
1FDA Drug Safety Communication: Prolia and Advanced CKDBoxed warning for severe hypocalcemia, CKD-mineral bone disorder assessment, supplementation, and monitoring
Medication safety reviewVerify the indication, current assessment, laboratory trend, timing, interactions, authorized action, and measurable follow-up.